DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer
Open Access
- 27 September 2004
- journal article
- research article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 57 (10), 1057-1062
- https://doi.org/10.1136/jcp.2004.016436
Abstract
Background: Recent studies have shown that minichromosome maintenance (MCM) proteins (Mcm2–7) may be useful proliferation markers in dysplasia and cancer in various tissues. Aims: To investigate the use of Mcm7 as a proliferation marker in 79 lymph node negative prostate cancers and compare it with Ki-67, a commonly used cell proliferation marker. Methods: The percentage of proliferating cells (proliferation index; PI) was calculated for basal and luminal epithelial cells in benign prostate tissue, prostatic intraepithelial neoplasia (PIN), and epithelial cells in adenocarcinoma. The PI for each biomarker was correlated with the preoperative prostate specific antigen concentration, the Gleason score, surgical resection margin status, and the AJCC pT stage for each patient. Results: The mean PIs for Ki-67 and Mcm7 were: benign luminal epithelium 0.7 and 1.2 and benign basal epithelium 0.8 and 8.2; PIN non-basal epithelium 4.9 and 10.6 and PIN basal epithelium 0.7 and 3.1; adenocarcinoma 9.8 and 22.7, respectively. Mcm7 had a significantly higher mean PI (pConclusion: Mcm7 may be a useful proliferation marker in prostatic neoplasia and warrants further evaluation as a complementary tool in the diagnosis of PIN and prostate carcinoma.Keywords
This publication has 50 references indexed in Scilit:
- Cancer Statistics, 2001CA: A Cancer Journal for Clinicians, 2001
- Stepwise Regulated Chromatin Assembly of MCM2–7 ProteinsPublished by Elsevier ,2000
- STEM CELL FEATURES OF BENIGN AND MALIGNANT PROSTATE EPITHELIAL CELLSJournal of Urology, 1998
- Proliferative Index Determination in Prostatic Carcinoma Tissue: Is There Any Additional Prognostic Value Greater Than That of Gleason Score, Ploidy and Pathological Stage?Journal of Urology, 1997
- Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1‐2MO prostatic adenocarcinomaInternational Journal of Cancer, 1994
- Evaluation of Ki‐67 Monoclonal Antibody as Prognostic Indicator for Prostatic CarcinomaBritish Journal of Urology, 1993
- Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinomaThe Journal of Pathology, 1992
- Growth fractions in human prostatic carcinoma determined by Ki‐67 immunostainingThe Journal of Pathology, 1988
- Cyclin/PCNA is the auxiliary protein of DNA polymerase-δNature, 1987
- Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferationInternational Journal of Cancer, 1983